{"nctId":"NCT01560403","briefTitle":"A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021","startDateStruct":{"date":"2012-05-21","type":"ACTUAL"},"conditions":["Short Bowel Syndrome"],"count":14,"armGroups":[{"label":"Teduglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Teduglutide"]}],"interventions":[{"name":"Teduglutide","otherNames":["Gattex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At completion of Study CL0600-021, subjects will be invited to participate in this trial if they meet the following criteria:\n\n  1. Completion of the 24-month study, CL0600-021, regardless if fully weaned from PN/I.V. support\n  2. Signed and dated informed consent form (ICF) to participate before any study-related procedures of Study TED-C11-001 are performed\n\nExclusion Criteria:\n\n* None","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Treatment-emergent Adverse Events","description":"As the primary intent of this study was to collect additional safety data, this outcomes measure will provide a summary of the treatment emergent adverse events. Based on the start date of each subject in this study and the study end date, not all subjects reached 12 months.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["Asthenic conditions","Diarrhoea","Abdominal pain","Anxiety symptoms","Benign neoplasms gastrointestinal"]}}}